

Efficacy results

The efficacy endpoint used in this trial is the subject global evaluation of rhinoconjunctivitis at visit 7, 9 11, 13 and 15 as Much better, Better, Same, Worse and Much worse.

Global evaluation	V7		V9		V11		V13		V15	
	N	%	N	%	N	%	N	%	N	%
Much better	17	38.64	13	34.21	8	24.2	6	20.00	1	3.33
Better	21	54.55	21	55.26	14	42.42	10	33.33	13	43.33
Same	2	4.55	1	2.63	7	21.21	7	23.33	5	16.6
Worse	1	2.27	3	7.89	4	12.12	6	20.00	11	36.67
Much worse							1	3.33		
Total	44	100	38	100	33	100	30	100	30	100